{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:56:42Z","timestamp":1740139002088,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Canc Educ"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone metastases are common in advanced breast cancer (BC) patients and increase the risk for skeletal-related events (SREs), which present a significant health and economic burden. Bone\u00a0targeting agents (BTAs) can improve health-related quality of life by delaying or preventing SREs; nevertheless, a significant portion of eligible BC patients are not receiving this therapy. A bone health education needs assessment survey was conducted to examine cancer-related bone health awareness and to identify opportunities to improve bone health education. Direct-to-patient outreach was used to recruit adult BC patients in the USA self-reporting a diagnosis of bone metastasis within the past 3 years. Of the 200 patients, 59% experienced at least one SRE prior to survey participation (44% radiation to bone, 29% bone fracture, 17% spinal cord compression, 15% surgery to bone), and 83% were currently receiving a BTA. Awareness of general cancer bone health, protection strategies against SREs, and screening tests were low to moderate. Patients currently not receiving a BTA were least knowledgeable about cancer bone health, with only 40% aware of BTAs as a protective strategy, and only 26% were very or extremely satisfied with the information received from healthcare providers. Sixty-two percent of patients wanted to receive information by more than one mode of communication. Notable gaps in bone health education were observed in bone metastatic BC patients at risk for SREs, suggesting the need for earlier and more effective communication and education strategies to promote appropriate BTA use and better health outcomes.<\/jats:p>","DOI":"10.1007\/s13187-023-02293-w","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T16:04:45Z","timestamp":1682697885000},"page":"1522-1530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Bone Health Awareness and Education in Breast Cancer Patients with Bone Metastasis in the USA"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-9534","authenticated-orcid":false,"given":"Darcy R.","family":"Flora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-7218","authenticated-orcid":false,"given":"Jennifer","family":"Schenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Cadieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Boike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"1","key":"2293_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"2293_CR2","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. Accessed September 27, 2021 from https:\/\/seer.cancer.gov"},{"issue":"6","key":"2293_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","volume":"26","author":"AB Mariotto","year":"2017","unstructured":"Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809\u2013815. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0889","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"2293_CR4","doi-asserted-by":"publisher","first-page":"27990","DOI":"10.18632\/oncotarget.15856","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S (2017) Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget 8(17):27990\u201327996. https:\/\/doi.org\/10.18632\/oncotarget.15856","journal-title":"Oncotarget"},{"issue":"1","key":"2293_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19(1):1091. https:\/\/doi.org\/10.1186\/s12885-019-6311-z","journal-title":"BMC Cancer"},{"issue":"20 Pt 2","key":"2293_CR6","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s\u20136249s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin Cancer Res"},{"key":"2293_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2407-11-29","volume":"11","author":"AO Jensen","year":"2011","unstructured":"Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29. https:\/\/doi.org\/10.1186\/1471-2407-11-29","journal-title":"BMC Cancer"},{"issue":"8","key":"2293_CR8","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cam4.1668","volume":"7","author":"Y Gong","year":"2018","unstructured":"Gong Y, Zhang J, Ji P, Ling H, Hu X, Shao ZM (2018) Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Med 7(8):4156\u20134169. https:\/\/doi.org\/10.1002\/cam4.1668","journal-title":"Cancer Med"},{"issue":"1","key":"2293_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","volume":"18","author":"RK Hernandez","year":"2018","unstructured":"Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH (2018) Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer 18(1):44. https:\/\/doi.org\/10.1186\/s12885-017-3922-0","journal-title":"BMC Cancer"},{"issue":"7","key":"2293_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2020.03.55","volume":"8","author":"JF Huang","year":"2020","unstructured":"Huang JF, Shen J, Li X, Rengan R, Silvestris N, Wang M, Derosa L, Zheng X, Belli A, Zhang XL, Li YM, Wu A (2020) Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med 8(7):482. https:\/\/doi.org\/10.21037\/atm.2020.03.55","journal-title":"Ann Transl Med"},{"key":"2293_CR11","doi-asserted-by":"publisher","unstructured":"Ryan C, Stoltzfus KC, Horn S, Chen H, Louie AV, Lehrer EJ, Trifiletti DM, Fox EJ, Abraham JA, Zaorsky NG (2020) Epidemiology of bone metastases. Bone 115783. https:\/\/doi.org\/10.1016\/j.bone.2020.115783","DOI":"10.1016\/j.bone.2020.115783"},{"issue":"16","key":"2293_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655\u20131664. https:\/\/doi.org\/10.1056\/NEJMra030831","journal-title":"N Engl J Med"},{"issue":"8","key":"2293_CR13","first-page":"695","volume":"30","author":"RE Coleman","year":"2016","unstructured":"Coleman RE (2016) Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer. Oncology 30(8):695\u2013702","journal-title":"Oncology"},{"issue":"149","key":"2293_CR14","first-page":"211","volume":"27","author":"M Yang","year":"2019","unstructured":"Yang M, Liu C, Yu X (2019) Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discov Med 27(149):211\u2013220","journal-title":"Discov Med"},{"issue":"3","key":"2293_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/03007995.2018.1558849","volume":"35","author":"D Henry","year":"2019","unstructured":"Henry D, von Moos R, Body JJ, Rider A, De Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y (2019) Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States. Curr Med Res Opin 35(3):375\u2013381. https:\/\/doi.org\/10.1080\/03007995.2018.1558849","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2293_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42(2):164\u2013175. https:\/\/doi.org\/10.1097\/01.mlr.0000108746.69256.45","journal-title":"Med Care"},{"issue":"1","key":"2293_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","volume":"131","author":"N Sathiakumar","year":"2012","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Brill I, Kilgore ML (2012) Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat 131(1):231\u2013238. https:\/\/doi.org\/10.1007\/s10549-011-1721-x","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2293_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3111\/13696998.2014.890937","volume":"17","author":"M Hagiwara","year":"2014","unstructured":"Hagiwara M, Delea TE, Chung K (2014) Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. J Med Econ 17(3):223\u2013230. https:\/\/doi.org\/10.3111\/13696998.2014.890937","journal-title":"J Med Econ"},{"issue":"10","key":"2293_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92(10):1869\u20131876. https:\/\/doi.org\/10.1038\/sj.bjc.6602551","journal-title":"Br J Cancer"},{"key":"2293_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","volume":"53","author":"A Lipton","year":"2016","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer 53:75\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.011","journal-title":"Eur J Cancer"},{"key":"2293_CR21","unstructured":"National Comprehensive Cancer Network (2020) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): breast cancer (Version 5.2020 - July 15, 2020). Accessed January 18, 2023 from https:\/\/www2.tri-kobe.org\/nccn\/guideline\/breast\/english\/breast.pdf"},{"key":"2293_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/CLEP.S85496","volume":"7","author":"RK Hernandez","year":"2015","unstructured":"Hernandez RK, Adhia A, Wade SW, O'Connor E, Arellano J, Francis K, Alvrtsyan H, Million RP, Liede A (2015) Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol 7:335\u2013345. https:\/\/doi.org\/10.2147\/CLEP.S85496","journal-title":"Clin Epidemiol"},{"key":"2293_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2147\/CLEP.S175063","volume":"10","author":"LJ McGrath","year":"2018","unstructured":"McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA, Brookhart MA, Hernandez RK (2018) Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. Clin Epidemiol 10:1349\u20131358. https:\/\/doi.org\/10.2147\/CLEP.S175063","journal-title":"Clin Epidemiol"},{"issue":"3","key":"2293_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jbo.2013.05.002","volume":"2","author":"B Hutton","year":"2013","unstructured":"Hutton B, Morretto P, Emmenegger U, Mazzarello S, Kuchuk I, Addison CL, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M (2013) Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: a patient survey. J Bone Oncol 2(3):105\u2013109. https:\/\/doi.org\/10.1016\/j.jbo.2013.05.002","journal-title":"J Bone Oncol"},{"issue":"11","key":"2293_CR25","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1007\/s00520-021-06238-1","volume":"29","author":"M Alzahrani","year":"2021","unstructured":"Alzahrani M, Clemons M, Sienkiewicz M, Shrem NS, McGee SF, Vandermeer L, Sehdev S, Savard MF, Awan A, Canil C, Hutton B, Pond G, Saunders D, Ng T (2021) Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. Support Care Cancer 29(11):6903\u20136912. https:\/\/doi.org\/10.1007\/s00520-021-06238-1","journal-title":"Support Care Cancer"},{"key":"2293_CR26","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.2147\/CMAR.S300063","volume":"13","author":"DR Flora","year":"2021","unstructured":"Flora DR, Carlson KB, Fuehrer DC, Cadieux B, Boike G, Schenfeld J, Lowe KA (2021) Assessment of bone health education in US multiple myeloma and solid tumor patients at risk for skeletal-related events. Cancer Manag Res 13:3529\u20133537. https:\/\/doi.org\/10.2147\/CMAR.S300063","journal-title":"Cancer Manag Res"},{"issue":"5","key":"2293_CR27","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.21037\/apm-20-1128","volume":"10","author":"CL Kent","year":"2021","unstructured":"Kent CL, McDuff SGR, Salama JK (2021) Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review. Ann Palliat Med 10(5):5954\u20135968. https:\/\/doi.org\/10.21037\/apm-20-1128","journal-title":"Ann Palliat Med"},{"issue":"4","key":"2293_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Schlijper R, Bauman GS, Laba J et al (2022) Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys 114(4):611\u2013616. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"2293_CR29","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/S0960-9776(19)31133-6","volume":"48","author":"R Coleman","year":"2019","unstructured":"Coleman R (2019) Clinical benefits of bone targeted agents in early breast cancer. Breast 48(Suppl 1):S92\u2013S96. https:\/\/doi.org\/10.1016\/S0960-9776(19)31133-6","journal-title":"Breast"}],"container-title":["Journal of Cancer Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-023-02293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13187-023-02293-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-023-02293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T03:44:28Z","timestamp":1695181468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13187-023-02293-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2293"],"URL":"https:\/\/doi.org\/10.1007\/s13187-023-02293-w","relation":{},"ISSN":["0885-8195","1543-0154"],"issn-type":[{"type":"print","value":"0885-8195"},{"type":"electronic","value":"1543-0154"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"21 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Western Institutional Review Board (WIRB Study Number 1258908), an independent ethical review board, and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all the patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"DRF is an employee of and holds stock in GRYT Health Inc. GRYT Health Inc. received funding from Amgen Inc. to design, conduct, and analyze data from this study and to prepare the manuscript. JS, HS, and KAL are employees of and hold stock in Amgen Inc. BC is a current employee of and holds stock in MEI Pharma Inc. and is a former employee of and holds stock in Amgen Inc. GB has no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}